var data={"title":"Pralidoxime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pralidoxime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6821?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pralidoxime-drug-information\" class=\"drug drug_general\">see &quot;Pralidoxime: Drug information&quot;</a> and <a href=\"topic.htm?path=pralidoxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pralidoxime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801639\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=12720\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212244\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Protopam Chloride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061315\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Anticholinesterase</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Organophosphate Poisoning</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061310\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pralidoxime-drug-information\" class=\"drug drug_general\">see &quot;Pralidoxime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Use in conjunction with atropine; atropine effects should be established before pralidoxime is administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Organophosphate poisoning: Note:</b> Administration IV is preferable; if IV route not feasible, may be given IM or SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Continuous infusion:</i>  Infants, Children, and Adolescents &le;16 years: Loading dose: IV: 20 to 50 mg/kg (maximum dose: 2,000 mg/dose); followed by continuous infusion at 10 to 20 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intermittent infusion:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &le;16 years: IV: Initial:  20 to 50 mg/kg (maximum dose: 2,000 mg/dose); repeat initial dose after 1 hour and repeat every 10 to 12 hours as needed if muscle weakness persists</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &gt;16 years: IV: Initial: 1,000 to 2,000 mg; may repeat bolus of 1,000 to 2,000 mg after 1 hour and repeat every 10 to 12 hours thereafter, as needed, if muscle weakness persists</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Mild symptoms:</i> IM: 15 mg/kg/dose; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 45 mg/kg; may administer doses in rapid succession if severe symptoms develop</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Severe symptoms:</i> IM: 15 mg/kg/dose; repeat twice in rapid succession to deliver a total dose of 45 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Persistent symptoms:</i> IM: May repeat the entire series (45 mg/kg in 3 divided doses) beginning ~1 hour after administration of the last injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Mild symptoms:</i> IM: 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1,800 mg; may administer doses in rapid succession if severe symptoms develop</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Severe symptoms:</i> IM: 600 mg; repeat twice in rapid succession to deliver a total dose of 1,800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Persistent symptoms:</i> IM: May repeat the entire series (1,800 mg in 3 divided doses) beginning ~1 hour after administration of the last injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Use in conjunction with atropine; atropine effects should be established before pralidoxime is administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticholinesterase poisoning (eg, neostigmine, pyridostigmine):</b> IV: 1,000 to 2,000 mg; followed by increments of 250 mg every 5 minutes as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Organophosphate poisoning: Note:</b> IV administration is preferable; if IV route not feasible, may be given IM or SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 1,000 to 2,000 mg; Maintenance: Repeat bolus of 1,000 to 2,000 mg after 1 hour and repeat every 10 to 12 hours thereafter, as needed if muscle weakness persists</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Mild symptoms:</i> IM: 600 mg; repeat as needed for persistent mild symptoms every 15 minutes to a maximum total dose of 1,800 mg; may administer doses in rapid succession if severe symptoms develop</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Severe symptoms:</i> IM: 600 mg; repeat twice in rapid succession to deliver a total dose of 1,800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Persistent symptoms:</i> IM: May repeat the entire series (1,800 mg in 3 divided doses) beginning ~1 hour after administration of the last injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: Dose should be reduced; no specific recommendations are provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212224\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Intramuscular, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protopam Chloride: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212210\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061319\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Use a 300 mg/mL solution; either autoinjector or reconstituted powder for injection may be used; in infants and children, administer intramuscularly in the anterolateral aspect of the thigh </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Infuse over 15 to 30 minutes; if maximally concentrated solution (50 mg/mL) may be administered over &ge;5 minutes not to exceed 200 mg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose (intermittent infusion): Infuse over 15 to 30 minutes a rate not to exceed 200 mg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212240\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061318\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg, nerve agents) [FDA approved in pediatric patients (age not specified) and adults]; control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium, neostigmine, pyridostigmine) [FDA approved in pediatric patients (age not specified) and adults]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212271\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pralidoxime may be confused with pramoxine, pyridoxine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protopam&reg; may be confused with protamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212269\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrest, hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, drowsiness, headache, paralysis, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT (transient), increased serum AST (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations, increased creatine phosphokinase, laryngospasm, muscle rigidity, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Accommodation disturbance, blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, hyperventilation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212231\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no absolute contraindications listed within the manufacturer&rsquo;s labeling. <b>Note:</b> According to the manufacturer, relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212214\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbamate poisoning: Pralidoxime is <b>not</b> indicated for the treatment of carbamate poisoning; acetylcholinesterase is weakly, but not permanently, affected by carbamates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; administration may precipitate a myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nonanticholinesterase poisoning: Pralidoxime is <b>not</b> indicated for the treatment of poisoning due to phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Clinical symptoms that are consistent with suspected organophosphate poisoning (eg, organophosphate anticholinesterase pesticides and nerve agents) should be treated with the antidote immediately; administration should not be delayed for confirmatory laboratory tests. Treatment should include proper evacuation and decontamination procedures as indicated; medical personnel should protect themselves from inadvertent contamination. Antidote administration is intended only for initial management; definitive and more intensive medical care is required following administration. Individuals should not rely solely on antidote for treatment; the concomitant use of atropine will be necessary and other supportive measures (eg, artificial respiration) may still be required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26072057\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Rapid IV infusion may be associated with temporary worsening of cholinergic manifestations (eg, tachycardia, laryngospasm, muscle rigidity, cardiac arrest) in adults; in children, muscle fasciculations, apnea, and convulsions have also been reported.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299930\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212218\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12720&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212220\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13459587\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. A case report did not show evidence of adverse events after pralidoxime administration during the second trimester (Kamha, 2005). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061314\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry, blood pressure and cardiac monitoring with IV administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212213\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reactivates cholinesterase that had been inactivated by phosphorylation due to exposure to organophosphate pesticides and cholinesterase-inhibiting nerve agents (eg, terrorism and chemical warfare agents such as sarin) by displacing the enzyme from its receptor sites; removes the phosphoryl group from the active site of the inactivated enzyme </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212230\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 0.6 to 2.7 L/kg; Severely poisoned pediatric patients (n=11; age: 0.8 to 18 years): ~9 L/kg (range: 1.7 to 13.8 L/kg) (Schexnayder 1998); may increase with increasing severity of organophosphate intoxication </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Apparent: 74 to 77 minutes; Poisoned patients (IM, IV): 3 to 4 hours; Pediatric patients (n=11; age: 0.8 to 18 years): 2.4 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IV: 5 to 15 minutes; IM: ~35 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% as metabolites and unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323722\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Protopam Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $104.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Pralidoxime Chloride Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/2 mL (2 mL): $39.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038776\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldopam (IN);</li>\n      <li>Contrathion (AR, BR, FR, GR, IT, TR);</li>\n      <li>Naprax (LK);</li>\n      <li>Neopam (LK);</li>\n      <li>Oridoxime (VN);</li>\n      <li>PAM (NZ);</li>\n      <li>Pam-A (SG, VN);</li>\n      <li>Pamcl (TW);</li>\n      <li>Pampara (MY, TW, VN);</li>\n      <li>Pamu (KR);</li>\n      <li>Pradox (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamha AA, Al Omary IY, Zalabany HA, et al, &quot;Organophosphate Poisoning in Pregnancy: A Case Report,&quot; <i>Basic Clin Pharmacol Toxicol</i>, 2005, 96(5):397-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pralidoxime-pediatric-drug-information/abstract-text/15853933/pubmed\" target=\"_blank\" id=\"15853933\">15853933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protopam injection powder, lyophilized, for solution (pralidoxime) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions LLC; December 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12720 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F22801639\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212244\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061315\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061310\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212224\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F212210\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061319\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F212240\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061318\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212271\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212269\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212231\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212214\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26072057\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299930\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212218\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212220\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13459587\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061314\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F212213\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F212230\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323722\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038776\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12720|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pralidoxime-drug-information\" class=\"drug drug_general\">Pralidoxime: Drug information</a></li><li><a href=\"topic.htm?path=pralidoxime-patient-drug-information\" class=\"drug drug_patient\">Pralidoxime: Patient drug information</a></li></ul></div></div>","javascript":null}